Drugs that contain Avapritinib

1. List of Ayvakit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(11 years from now)

Do you want to check out AYVAKIT patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 9, 2025
New Indication (I) Jun 16, 2024
Orphan Drug Exclusivity (ODE) Jan 9, 2027

NCE-1 date: 2024-01-10

Market Authorisation Date: 09 January, 2020

Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastoc...

Dosage: TABLET;ORAL

More Information on Dosage

AYVAKIT family patents

9

United States

3

Hungary

2

Spain

2

Portugal

2

Poland

2

Japan

2

China

2

Lithuania

2

European Union

1

Australia

1

Israel

1

Croatia

1

Korea, Republic of

1

Canada

1

Netherlands

1

New Zealand

1

Denmark

1

Uruguay

1

Cyprus

1

Singapore

1

Philippines

1

Russia

1

Norway

1

Hong Kong

1

Slovenia

1

Mexico

1

Argentina

1

Brazil

1

RS

1

South Africa

1

Taiwan

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic